Rockefeller Capital Management’s Coherus Oncology CHRS Stock Holding History

Rockefeller Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$454	Hold	324	–	–	﹤0.01%	4606
2026 Q1	$548	Hold	324	–	–	﹤0.01%	4553
2025 Q4	$460	Hold	324	–	–	﹤0.01%	4537
2025 Q3	$531	Buy	+324	New	+$360	﹤0.01%	4266
2023 Q1	–	Sell	-449	Closed	-$3K	–	2299
2022 Q4	$3K	Hold	449	–	–	﹤0.01%	3442
2022 Q3	$4K	Sell	449 -106	-19%	-$1.07K	﹤0.01%	3384
2022 Q2	$4K	Buy	555 +231	+71%	+$2.01K	﹤0.01%	3513
2022 Q1	$4K	Sell	324 -11	-3%	-$140	﹤0.01%	3392
2021 Q4	$5K	Sell	335 -106	-24%	-$1.85K	﹤0.01%	3247
2021 Q3	$7K	Hold	441	–	–	﹤0.01%	3030
2021 Q2	$6K	Hold	441	–	–	﹤0.01%	2959
2021 Q1	$6K	Buy	+441	New	+$7.49K	﹤0.01%	2822
2020 Q1	–	Sell	-4	Closed	–	–	2368
2019 Q4	$0	Buy	+4	New	+$74	﹤0.01%	2066

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Rockefeller Capital Management's CHRS Position: Q2 2026 in Review

Rockefeller Capital Management held its Coherus Oncology (CHRS) position steady in Q2 2026 at 324 shares worth $454. The position accounts for ﹤0.01% of the portfolio, ranked #4606.

Rockefeller Capital Management first reported a position in CHRS in Q4 2019 and has held it in 13 quarters since. The position peaked at $7K in Q3 2021. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

Rockefeller Capital Management held 324 shares of Coherus Oncology worth $454 as of Q2 2026.
Rockefeller Capital Management left its Coherus Oncology share count unchanged in Q2 2026.
Coherus Oncology made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4606 holding.
Rockefeller Capital Management first reported a position in Coherus Oncology in Q4 2019 and has held it in 13 quarters since.
Rockefeller Capital Management's Coherus Oncology position peaked at $7K in Q3 2021.
146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.